Exelixis (EXEL) Receives Daily News Sentiment Score of 0.20

Headlines about Exelixis (NASDAQ:EXEL) have been trending somewhat positive on Friday, Accern Sentiment Analysis reports. The research group ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Exelixis earned a daily sentiment score of 0.20 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 45.9749819814512 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:

A number of research analysts have issued reports on EXEL shares. Royal Bank of Canada assumed coverage on Exelixis in a report on Thursday, September 14th. They set an “outperform” rating and a $32.00 price objective for the company. Leerink Swann lowered Exelixis from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $34.00 to $28.00 in a research note on Friday, September 22nd. Oppenheimer restated a “hold” rating on shares of Exelixis in a research note on Monday, September 25th. Needham & Company LLC restated a “buy” rating and issued a $30.00 target price on shares of Exelixis in a research note on Monday, October 2nd. Finally, Zacks Investment Research upgraded Exelixis from a “hold” rating to a “buy” rating and set a $29.00 target price for the company in a research note on Tuesday, October 10th. Six investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Exelixis has a consensus rating of “Buy” and a consensus price target of $32.13.

Exelixis (NASDAQ:EXEL) traded up $0.30 during trading hours on Friday, hitting $30.38. The stock had a trading volume of 2,026,300 shares, compared to its average volume of 2,550,000. Exelixis has a fifty-two week low of $16.72 and a fifty-two week high of $32.50. The company has a market cap of $8,990.00, a PE ratio of 62.00, a PEG ratio of 0.95 and a beta of 1.88.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported $0.26 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.08 by $0.18. The business had revenue of $152.50 million for the quarter, compared to analysts’ expectations of $104.91 million. Exelixis had a return on equity of 105.47% and a net margin of 36.80%. Exelixis’s revenue for the quarter was up 145.2% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.04) EPS. sell-side analysts expect that Exelixis will post 0.49 EPS for the current year.

In other Exelixis news, Director Alan M. Garber sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $30.30, for a total value of $454,500.00. Following the sale, the director now owns 64,829 shares in the company, valued at approximately $1,964,318.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 5.10% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://ledgergazette.com/2018/01/13/exelixis-exel-earns-daily-media-sentiment-rating-of-0-20.html.

Exelixis Company Profile

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply